高级检索
当前位置: 首页 > 详情页

Attenuation of diabetic nephropathy by Chaihuang-Yishen granule through anti-inflammatory mechanism in streptozotocin-induced rat model of diabetics

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]China Japan Friendship Hosp, Inst Clin Med Sci, Dept Pharmacol, Beijing 100029, Peoples R China [2]Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada [3]China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China
出处:
ISSN:

关键词: Diabetic nephropathy Chinese herbs Anti-inflammatory NF-kappa B

摘要:
Ethnopharmacological relevance: Traditional Chinese medical herbs have been used in China for a long time to treat different diseases. Based on traditional Chinese medicine (TCM) principle, Chaihuang-Yishen granule (CHYS) was developed and has been employed clinically to treat chronic kidney disease including diabetic nephropathy (DN). The present study was designed to investigate its mechanism of action in treatment of DN. Materials and methods: Diabetic rats were established by having a right uninephrectomy plus a single intraperitoneal injection of STZ. Rats were divided into four groups of sham, diabetes, diabetes with CHYS and diabetes with fosinopril. CHYS and fosinopril were given to rats by gavage for 20 weeks. Samples from blood, urine and kidney were collected for biochemical, histological, immunohistochemical and molecular analyses. Results: Rats treated with CHYS showed reduced 24 h urinary protein excretion, decreased serum TC and TG levels, but CHYS treatment did not affect blood glucose level. Glomerular mesangial expansion and tubulointerstitial fibrosis in diabetic rats were significantly alleviated by CHYS treatment. Moreover, CHYS administration markedly reduced mRNA levels of NF-kappa B p65 and TGF-beta 1, as well as decreased protein levels of NF-kappa B p65, MCP-1, TNF-alpha and TGF-beta 1 in the kidney of diabetic rats. Conclusions: CHYS ameliorates renal injury in diabetic rats through reduction of inflammatory cytokines and their intracellular signaling. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 3 区 医学
小类 | 2 区 全科医学与补充医学 3 区 药物化学 3 区 药学 3 区 植物科学
最新[2025]版:
大类 | 2 区 医学
小类 | 1 区 全科医学与补充医学 1 区 药学 2 区 药物化学 2 区 植物科学
JCR分区:
出版当年[2012]版:
Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 PLANT SCIENCES Q2 PHARMACOLOGY & PHARMACY Q2 CHEMISTRY, MEDICINAL
最新[2023]版:
Q1 CHEMISTRY, MEDICINAL Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 PHARMACOLOGY & PHARMACY Q1 PLANT SCIENCES

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2012版] 出版当年五年平均[2008-2012] 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者单位: [1]China Japan Friendship Hosp, Inst Clin Med Sci, Dept Pharmacol, Beijing 100029, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)